EGF Theramed Health Corp. engages in the development of psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression, as well as natural health and wellness products. The company is headquartered in Vancouver, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.0515727464710459 | N/A |
Market Cap | $515.15K | N/A |
Shares Outstanding | 9.99M | 363.47% |
Employees | 0 | N/A |
Shareholder Equity | -2.48M | 6.14% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.86 | N/A |
P/B Ratio | -0.21 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.1907 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$472.64K | N/A |
EPS | -0.06 | N/A |
Earnings Yield | -1.16 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $142.27K | N/A |
Total Debt | $982.08K | N/A |
Cash on Hand | $8.61K | N/A |
Debt to Equity | -0.7919 | 0.15% |
Cash to Debt | 0.0088 | -29.98% |
Current Ratio | 0.1090 | 3.64% |